scholarly journals Characterization of HIV drug resistance mutations among patients failing first-line antiretroviral therapy from a tertiary referral center in Lusaka, Zambia

2015 ◽  
Vol 87 (7) ◽  
pp. 1149-1157 ◽  
Author(s):  
Lillian Seu ◽  
Lloyd B. Mulenga ◽  
Mpanji Siwingwa ◽  
Izukanji Sikazwe ◽  
Nason Lambwe ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Resistance Mutations ◽  
First Line ◽  
Tertiary Referral ◽  
Hiv Drug Resistance ◽  
Tertiary Referral Center ◽  
Referral Center ◽  
Drug Resistance Mutations

scholarly journals Prevalence and Evolution of Low Frequency HIV Drug Resistance Mutations Detected by Ultra Deep Sequencing in Patients Experiencing First Line Antiretroviral Therapy Failure

PLoS ONE ◽  
2014 ◽  
Vol 9 (1) ◽  
pp. e86771 ◽  
Author(s):  
Marie-Anne Vandenhende ◽  
Pantxika Bellecave ◽  
Patricia Recordon-Pinson ◽  
Sandrine Reigadas ◽  
Yannick Bidet ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Deep Sequencing ◽  
Low Frequency ◽  
Resistance Mutations ◽  
Therapy Failure ◽  
First Line ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations

scholarly journals HIV Drug Resistance Mutations Detection by Next-Generation Sequencing during Antiretroviral Therapy Interruption in China

Pathogens ◽  
2021 ◽  
Vol 10 (3) ◽  
pp. 264
Author(s):  
Miaomiao Li ◽  
Shujia Liang ◽  
Chao Zhou ◽  
Min Chen ◽  
Shu Liang ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Next Generation Sequencing ◽  
Antiretroviral Therapy ◽  
Detection Threshold ◽  
Next Generation ◽  
Resistance Mutations ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations ◽  
Therapy Interruption ◽  
Generation Sequencing

Patients with antiretroviral therapy interruption have a high risk of virological failure when re-initiating antiretroviral therapy (ART), especially those with HIV drug resistance. Next-generation sequencing may provide close scrutiny on their minority drug resistance variant. A cross-sectional study was conducted in patients with ART interruption in five regions in China in 2016. Through Sanger and next-generation sequencing in parallel, HIV drug resistance was genotyped on their plasma samples. Rates of HIV drug resistance were compared by the McNemar tests. In total, 174 patients were included in this study, with a median 12 (interquartile range (IQR), 6–24) months of ART interruption. Most (86.2%) of them had received efavirenz (EFV)/nevirapine (NVP)-based first-line therapy for a median 16 (IQR, 7–26) months before ART interruption. Sixty-one (35.1%) patients had CRF07_BC HIV-1 strains, 58 (33.3%) CRF08_BC and 35 (20.1%) CRF01_AE. Thirty-four (19.5%) of the 174 patients were detected to harbor HIV drug-resistant variants on Sanger sequencing. Thirty-six (20.7%), 37 (21.3%), 42 (24.1%), 79 (45.4%) and 139 (79.9) patients were identified to have HIV drug resistance by next-generation sequencing at 20% (v.s. Sanger, p = 0.317), 10% (v.s. Sanger, p = 0.180), 5% (v.s. Sanger, p = 0.011), 2% (v.s. Sanger, p < 0.001) and 1% (v.s. Sanger, p < 0.001) of detection thresholds, respectively. K65R was the most common minority mutation, of 95.1% (58/61) and 93.1% (54/58) in CRF07_BC and CRF08_BC, respectively, when compared with 5.7% (2/35) in CRF01_AE (p < 0.001). In 49 patients that followed-up a median 10 months later, HIV drug resistance mutations at >20% frequency such as K103N, M184VI and P225H still existed, but with decreased frequencies. The prevalence of HIV drug resistance in ART interruption was higher than 15% in the survey. Next-generation sequencing was able to detect more minority drug resistance variants than Sanger. There was a sharp increase in minority drug resistance variants when the detection threshold was below 5%.

scholarly journals Predictors of HIV Drug‐Resistance Mutations in a Large Antiretroviral‐Naive Cohort Initiating Triple Antiretroviral Therapy

2005 ◽  
Vol 191 (3) ◽  
pp. 339-347 ◽  
Author(s):  
P. Richard Harrigan ◽  
Robert S. Hogg ◽  
Winnie W. Y. Dong ◽  
Benita Yip ◽  
Brian Wynhoven ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Resistance Mutations ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations

HIV drug resistance mutations among patients failing second-line antiretroviral therapy in Rwanda

2015 ◽  
Vol 20 (3) ◽  
pp. 253-259 ◽  
Author(s):  
Jean d’Amour Ndahimana ◽  
David J Riedel ◽  
Ribakare Muhayimpundu ◽  
Sabin Nsanzimana ◽  
Gad Niyibizi ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Second Line ◽  
Resistance Mutations ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations ◽  
Second Line Antiretroviral Therapy

scholarly journals Prevalence of HIV drug-resistance mutations in HIV-infected Mexican patients heavily experienced to antiretroviral therapy

2010 ◽  
Vol 13 (Suppl 4) ◽  
pp. P139
Author(s):  
JE Gaytán-Martínez ◽  
JA Mata-Marín ◽  
F Gutierrez-Escolano ◽  
L Pérez-Saleme ◽  
S Treviño-Pérez ◽  
...  
Keyword(s):  
Drug Resistance ◽  
Antiretroviral Therapy ◽  
Resistance Mutations ◽  
Hiv Drug Resistance ◽  
Drug Resistance Mutations ◽  
Mexican Patients
Sign in / Sign up

Export Citation Format

Share Document